Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Xultophy

Sanofi reception

Sanofi and Lexicon collaborate on new medication for diabetes

Plan to develop new investigational drugsotagliflozin

Sanofi reception

Sanofi and Hanmi collaborate on diabetes treatments

Aims to optimise efficacy of medications

Sanofi reception

Sanofi forges $1.5bn cancer partnership with BioNTech

Set to develop five cancer therapies

- PMLiVE

Novo Nordisk finally bags insulin degludec approval in US

Aims to get Tresiba and Ryzodeg back on course 

- PMLiVE

Sanofi posts positive data for MS drug Aubagio

Phase III study shows drug slows brain volume loss

Novo launches online news channel for haemophilia patients

New medical information website aims to be a 'simple, centralised repository'

- PMLiVE

Express Scripts ‘will pay $750m on PCSK9 inhibitors next year’

Amgen's Repatha and Sanofi's Praluent included

- PMLiVE

Genzyme opts into gene silencing therapy for haemophilia

Interim results show positive benefits for ALN-AT3

- PMLiVE

Novo Nordisk appoints new senior principal clinical scientist

Stephen Gough joins the Danish diabetes giant

Sanofi reception

Sanofi’s lixisenatide is back under FDA review

Brings GLP-1 agonist closer to US market

Eli Lilly HQ

Lilly set to launch Lantus biosimilar in the US next year

Settlement ends the company's legal dispute with Sanofi

- PMLiVE

New data arms Novo Nordisk for insulin battle with Sanofi

Tresibaand Xultophy boosted by studies presented at EASD 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links